Skip to main content

Regeneron Pharmaceuticals balance sheet

  • REGN · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$955.47+0.45%Close 13 Nov 2026 · Market value $102.5B

At the end of fiscal 2025 (the year to 31 Dec 2025), Regeneron Pharmaceuticals reported total assets of $40.56B, $3.12B in cash and equivalents, $2.25B of total debt; shareholders' equity was $31.26B.

From Regeneron Pharmaceuticals's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025.

Annual

Regeneron Pharmaceuticals balance sheet, annual
USDFY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$247.8M$207.1M$112.6M$483.6M$230.3M$535.6M$648.7M$809.1M$535.2M$812.7M$1.47B$1.62B$2.19B$2.89B$3.11B$2.73B$2.49B$3.12B
Short-term investments—$134.3M$136.8M$43.33M$77.82M$158.4M$251.8M$236.1M$503.5M$596.8M$1.34B$1.60B$1.39B$2.81B$4.64B$8.11B$6.52B$5.49B
Cash and short-term investments$247.8M$341.3M$249.4M$526.9M$308.1M$694.0M$900.5M$1.05B$1.04B$1.41B$2.81B$3.21B$3.59B$5.69B$7.74B$10.84B$9.01B$8.61B
Accounts receivable—$2.87M$2.31M$28.25M$593.2M$787.1M$739.4M$1.15B$1.34B$1.54B$1.72B$2.10B$4.11B$6.04B$5.33B$5.67B$6.21B$5.74B
Inventory———$16.61M$28.64M$70.35M$128.9M$238.6M$399.4M$726.1M$1.15B$1.42B$1.92B$1.95B$2.40B$2.58B$3.09B$3.20B
Current assets—$425.5M$357.6M$665.8M$1.21B$1.80B$2.08B$2.92B$3.18B$4.33B$6.45B$7.69B$9.78B$14.01B$15.88B$19.48B$18.66B$18.02B
Property, plant and equipment—$259.7M$347.4M$368.0M$379.9M$527.0M$974.3M$1.59B$2.08B$2.36B$2.58B$2.89B$3.22B$3.48B————
Acquired intangibles—————————————$6.70M$915.5M$1.04B$1.15B$1.26B
Long-term investments—$47.08M$370.1M$275.9M$271.2M$389.9M$460.2M$632.2M$864.3M$1.49B$1.75B$3.26B$3.14B$6.84B$6.59B$5.40B$8.90B$10.26B
Total assets—$741.2M$1.09B$1.32B$2.08B$2.95B$3.84B$5.61B$6.97B$8.76B$11.73B$14.81B$17.16B$25.43B$29.21B$33.08B$37.76B$40.56B
Accounts payable—————————$178.2M$218.2M$418.1M$475.5M$564.0M$589.2M$606.6M$789.5M$939.0M
Unearned revenue, current—$27.02M$54.72M$51.64M$50.83M$47.00M$74.03M$153.5M$231.7M$320.1M$452.5M$591.7M$577.7M$442.0M$477.9M$458.9M$627.7M$553.0M
Short-term borrowings———————————$0.00——————
Current liabilities—$93.58M$109.1M$148.3M$163.6M$298.8M$654.7M$811.2M$1.24B$1.14B$1.44B$2.10B$2.70B$3.93B$3.14B$3.42B$3.94B$4.37B
Long-term debt · non-current———————————$0.00$1.98B$1.98B$1.98B$1.98B$1.98B$1.99B
Operating lease liability———————————$23.60M———$87.70M$234.4M$266.8M
Finance lease liability———————————$713.9M$717.2M$719.7M$720.0M$720.0M$720.0M$720.0M
Total liabilities—$344.4M$561.6M$837.9M$835.1M$998.9M$1.29B$1.95B$2.52B$2.62B$2.98B$3.72B$6.14B$6.67B$6.55B$7.11B$8.41B$9.30B
Retained earnings—−$941.1M−$1.05B−$1.27B−$517.1M−$92.69M$216.6M$852.7M$1.75B$2.95B$5.25B$7.38B$10.89B$18.97B$23.31B$27.26B$31.67B$35.80B
Shareholders' equity$421.5M$396.8M$527.8M$485.7M$1.25B$1.95B$2.55B$3.65B$4.45B$6.14B$8.76B$11.09B$11.03B$18.77B$22.66B$25.97B$29.35B$31.26B
Total liabilities and equity—$741.2M$1.09B$1.32B$2.08B$2.95B$3.84B$5.61B$6.97B$8.76B$11.73B$14.81B$17.16B$25.43B$29.21B$33.08B$37.76B$40.56B
Total debt——$0.00$275.0M$296.5M$320.3M$146.8M$0.00———$737.5M$1.98B$1.98B$2.05B$2.07B$2.22B$2.25B
Net debt——−$249.4M−$251.9M−$11.58M−$373.7M−$753.7M−$1.05B———−$2.48B−$1.61B−$3.71B−$5.69B−$8.77B−$6.79B−$6.35B
Net working capital—$124.9M$136.0M$33.90M$812.2M$962.5M$781.4M$1.29B$1.40B$2.39B$3.54B$3.97B$4.89B$7.20B$9.64B$13.33B$12.23B$10.54B
Shares outstanding · period end—78.9M87.2M90.7M——————————————

Quarterly

Regeneron Pharmaceuticals balance sheet, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Cash and equivalents$2.73B$2.60B$1.92B$2.01B$2.49B$3.09B$2.00B$2.51B$3.12B$2.96B$2.46B$3.66B
Short-term investments$8.11B$7.92B$7.89B$7.78B$6.52B$5.26B$5.47B$5.94B$5.49B$5.79B$5.54B$5.64B
Cash and short-term investments$10.84B$10.52B$9.81B$9.80B$9.01B$8.35B$7.47B$8.44B$8.61B$8.75B$7.99B$9.30B
Accounts receivable$5.67B$5.22B$5.72B$6.11B$6.21B$5.56B$5.61B$5.69B$5.74B$5.73B$6.57B$7.58B
Inventory$2.58B$2.71B$2.87B$3.02B$3.09B$3.19B$3.21B$3.25B$3.20B$3.10B$3.08B$2.89B
Current assets$19.48B$18.87B$19.08B$19.33B$18.66B$17.57B$16.86B$17.98B$18.02B$18.21B$18.45B$20.80B
Acquired intangibles$1.04B$1.06B$1.10B$1.12B$1.15B$1.17B$1.35B$1.38B$1.26B$1.29B$1.31B$1.32B
Long-term investments$5.40B$6.98B$7.72B$8.49B$8.90B$9.28B$10.06B$10.29B$10.26B$9.79B$9.83B$9.56B
Total assets$33.08B$34.37B$36.09B$37.44B$37.76B$37.55B$38.22B$40.17B$40.56B$40.87B$41.73B$44.41B
Accounts payable$606.6M$671.3M$561.7M$497.3M$789.5M$705.5M$723.9M$903.8M$939.0M$1.03B$1.16B$1.14B
Unearned revenue, current$458.9M$516.7M$586.0M$627.2M$627.7M$619.3M$481.9M$545.6M$553.0M$636.2M$684.8M$749.8M
Current liabilities$3.42B$3.58B$3.51B$3.66B$3.94B$3.57B$3.67B$4.43B$4.37B$5.11B$5.53B$6.20B
Long-term debt · non-current$1.98B$1.98B$1.98B$1.98B$1.98B$1.98B$1.99B$1.99B$1.99B$1.99B$1.99B$1.99B
Operating lease liability$87.70M———$234.4M———$266.8M———
Finance lease liability$720.0M———$720.0M———$720.0M———
Total liabilities$7.11B$7.38B$7.88B$8.12B$8.41B$8.16B$8.28B$9.21B$9.30B$9.45B$10.02B$10.91B
Retained earnings$27.26B$27.98B$29.41B$30.76B$31.67B$32.38B$33.68B$35.05B$35.80B$36.42B$37.62B$39.47B
Shareholders' equity$25.97B$26.99B$28.21B$29.33B$29.35B$29.39B$29.94B$30.96B$31.26B$31.42B$31.71B$33.50B
Total liabilities and equity$33.08B$34.37B$36.09B$37.44B$37.76B$37.55B$38.22B$40.17B$40.56B$40.87B$41.73B$44.41B
Total debt$2.07B$1.98B$1.98B$1.98B$2.22B$1.98B$1.99B$1.99B$2.25B$1.99B$1.99B$1.99B
Net debt−$8.77B−$8.54B−$7.83B−$7.81B−$6.79B−$6.36B−$5.48B−$6.46B−$6.35B−$6.77B−$6.01B−$7.31B
Net working capital$13.33B$12.69B$13.65B$13.66B$12.23B$10.91B$11.20B$11.05B$10.54B$10.14B$10.46B$10.93B

The main figures as JSON and plain text. See data and methodology.

REGN in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.